Measles Cases and Deaths Rose At “Staggering” Rate Last Year, WHO And CDC Report
WHO and CDC have previously warned the world is far from reaching the immunization level for herd immunity against measles, which is estimated to be at least 95% of the population. But there hasn’t been any progress in reversing the pandemic-driven decline in vaccinations in low-income countries, where the risk of death from measles is highest. Full Access: Axios
Toxoplasma gondii IgG Serointensity Is Positively Associated with Frailty
A common, cat-borne parasite already associated with risk-taking behavior and mental illness in humans may also contribute to exhaustion, loss of muscle mass, and other signs of “frailty” in older adults. This first reported association between T. gondii and frailty is limited by a cross-sectional design and warrants replication. While certain biomarkers of inflammation were associated with both T. gondii IgG serointensity and frailty, they did not fully mediate the T. gondii–frailty association. Full Access: The Journal of Gerontology
FDA Approves Cosentyx for HS
The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade. Cosentyx for HS is approved as a 300 mg dose, administered every four weeks, with the option to increase to every two weeks if the patient has an inadequate response. Full Access: Practical Dermatology
Major Risk Factor for Sepsis
This study found that socioeconomic deprivation and clinical morbidities, including chronic kidney disease, organ transplantation, uncontrolled diabetes, various forms of malignancy, chronic liver disease, neurological diseases, immunosuppressive conditions, and learning disabilities, increased the risk of developing community-acquired nonCOVID-19 sepsis. Full Access: The Lancet
